[go: up one dir, main page]

ZA201206518B - Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency - Google Patents

Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency

Info

Publication number
ZA201206518B
ZA201206518B ZA2012/06518A ZA201206518A ZA201206518B ZA 201206518 B ZA201206518 B ZA 201206518B ZA 2012/06518 A ZA2012/06518 A ZA 2012/06518A ZA 201206518 A ZA201206518 A ZA 201206518A ZA 201206518 B ZA201206518 B ZA 201206518B
Authority
ZA
South Africa
Prior art keywords
carnitine
insuficiency
propionyl
prevention
treatment
Prior art date
Application number
ZA2012/06518A
Inventor
Mohamed Ashraf Virmani
Aleardo Koverech
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51844410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201206518(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP10152363A external-priority patent/EP2353596A1/en
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of ZA201206518B publication Critical patent/ZA201206518B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA2012/06518A 2010-02-02 2012-08-30 Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency ZA201206518B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10152363A EP2353596A1 (en) 2010-02-02 2010-02-02 Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency
US32253210P 2010-04-09 2010-04-09
PCT/IB2011/000200 WO2011095882A1 (en) 2010-02-02 2011-02-07 Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency

Publications (1)

Publication Number Publication Date
ZA201206518B true ZA201206518B (en) 2013-05-29

Family

ID=51844410

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2012/06518A ZA201206518B (en) 2010-02-02 2012-08-30 Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency

Country Status (7)

Country Link
CA (1) CA2787470C (en)
CL (1) CL2012001740A1 (en)
HR (1) HRP20140785T1 (en)
MY (1) MY182607A (en)
PH (1) PH12012501249A1 (en)
SM (1) SMT201400121B (en)
ZA (1) ZA201206518B (en)

Also Published As

Publication number Publication date
HRP20140785T1 (en) 2014-11-07
CA2787470A1 (en) 2011-08-11
SMT201400121B (en) 2014-11-10
CA2787470C (en) 2018-03-27
PH12012501249A1 (en) 2017-04-07
CL2012001740A1 (en) 2012-11-09
MY182607A (en) 2021-01-26

Similar Documents

Publication Publication Date Title
PL2531189T3 (en) Combination composition, comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insufficiency
EP2440209A4 (en) Compositions and methods for the prevention and treatment of heart failure
IL216800A (en) Composition for the treatment of dry eye syndrome
IL225471B (en) Compositions for the prevention and treatment of cancer
WO2012125832A3 (en) Antimicrobial agents
EP2654745A4 (en) Composition for the treatment of skin conditions
SG10201501579WA (en) Composition comprising as active ingredient l-carnitine in combination with hydroxykynurennine-0-beta-dl-glucoside, for the prevention and/or treatment of pathologies of the eye due to ultraviolet radiation
WO2012017321A3 (en) Treatment for dyslipidemia
PL2538918T3 (en) Citicoline for the treatment of glaucoma
EP3037093A4 (en) Composition containing monoacetyldiacylglycerol compound as active ingredient for preventing or treating chronic obstructive pulmonary diseases
IT1397446B1 (en) COMPOSITIONS COMPRISING AMINO ACIDS FOR PREVENTION AND / OR TREATMENT OF RENAL DISORDERS.
GB0917745D0 (en) Compositions for the prevention or treatment of migraine
PT2460509T (en) Composition for the treatment of warts
ZA201206518B (en) Combination composition,comprising as active ingredient l-carnitine or propionyl l-carnitine, for the prevention or treatment of chronic venous insuficiency
WO2014053962A3 (en) Compositions and methods for treatment of diabetes and pre-diabetes
PL2686005T3 (en) Topical compositions comprising diaminooxidase for the treatment or prevention of diseases associated with high histamine levels which involve an increase in pain
WO2011042077A3 (en) Transdermal therapeutic systems containing 4-n-butylresorcinol
WO2012013505A3 (en) Composition comprising oxalysine
RS55061B1 (en) Novel amino-pyrroline derivatives, and use thereof in the prevention and/or treatment of metabolic syndrome
HUP1100597A2 (en) Primycin or its components or combination for the treatment or prevention of infestations by special organisms
HK1181051A (en) Analogues for the treatment or prevention of flavivirus infections
HK1169604A (en) Compositions and methods for the prevention and treatment of heart failure
EP2696879A4 (en) Use of s-adenosylmethionine, vitamin e, and vitamin c for the prevention and treatment of cardiovascular dysfunction
PL1996207T3 (en) Compositions comprising chitosan suitable for comprehensive therapeutic treatment or comprehensive prevention of the metabolic syndrome
HUP1100268A2 (en) Nasale composition for the prevention of venous trombosis